Clinical trials: HIV/AIDS
Mild Cognitive Impairment
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.
- Trial name
- NCT02572323
- Testing
- Tesamorelin
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- University of California, San Diego
HIV Infections, Sexually Transmitted Diseases
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
The purpose of this study is to determine the safety of and immune response to a new human papillomavirus (HPV) vaccine in HIV (Human immunodeficiency virus) infected children between the ages of 7 and 12 years.
- Trial name
- NCT00339040
- Testing
- Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
MyPEEPS Mobile for Young Transgender Men
The proposed MyPEEPS intervention for young transgender men is a novel and evidence-driven intervention using mobile technology to deliver HIV prevention information to high risk youth.
- Trial name
- NCT05424718
- Testing
- MyPEEPS Mobile
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV Disease
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
The purpose of this study was to compare the use of lamivudine (3TC) or emtricitabine (FTC) alone vs. continuing a failing highly active antiretroviral therapy (HAART) regimen in HIV infected children, adolescents and young…
- Trial name
- P1094 (NCT01338025)
- Testing
- HAART regimen, 3TC or FTC monotherapy
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 33 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Tuberculosis, HIV I Infection
ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa
This study will compare community-delivered, multi-month dispensing of tuberculosis preventive therapy (TPT) to standard-of-care clinic-based TPT delivery in a population of South African adults who are recommended to receive TB…
- Trial name
- ThiPhiSA (NCT06214910)
- Testing
- Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP), Clinic-link TPT
- Where
- South Africa
- Volunteers
- 301 people
- Sponsor
- University of Washington
HIV Prevention
ATN 151 Work-to-Prevent: Employment as HIV Prevention
The investigators aim to pilot-test a novel social and structural-level HIV intervention for YMSM and YTW of color ages 16-24.
- Trial name
- W2P (NCT03313310)
- Testing
- Employment Intervention
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Human Immunodeficiency Virus
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents.
- Trial name
- NCT00791700
- Testing
- Maraviroc
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- ViiV Healthcare
HIV Disease
Therapy to Elevate CD4 Counts in HIV-1 Disease
For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment for patients who have inherited alpha-1-proteinase inhibitor deficiency.
- Trial name
- NCT01370018
- Testing
- alpha-1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
HIV
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect…
- Trial name
- NCT01003990
- Testing
- Atazanavir, Atazanavir/Ritonavir, Tenofovir/Emtricitabine
- Where
- 88 sites in United States, Argentina and 23 more
- Volunteers
- 710 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine
Summary: Chloroquine is a medication that in laboratory settings has significant anti-HIV effects in HIV infected T-cells. Chloroquine has been used safely for over 60 years for malaria treatment and prevention, and it also has…
- Trial name
- NCT00308620
- Testing
- chloroquine phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Minnesota
HIV, HIV Infections
HIV Persistence and Viral Reservoirs
Although highly active antiretroviral therapy (HAART) decreases HIV-associated mortality, it does not to completely restore health.
- Trial name
- NCT01025427
- Testing
- Raltegravir, tenofovir/emtricitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
HIV/AIDS, Cancer
Web-Based Cognitive Behavioral Stress Management for Latino Sexual Minority Men Living With HIV and Cancer
This is a one year study to develop and test a culturally-tailored, web-based cognitive behavioral stress management (CBSM) intervention for Latino sexual minority men living with both HIV and cancer.
- Trial name
- C-SmartManage (NCT03993054)
- Testing
- Culturally-tailored cognitive behavioral stress management
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Miami
Acquired Immunodeficiency Syndrome, HIV Infection
Multicenter, Safety Study Of Maraviroc
To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.
- Trial name
- NCT00478231
- Testing
- Maraviroc
- Where
- 16 sites in Brazil
- Volunteers
- 209 people
- Sponsor
- ViiV Healthcare
HIV-1 Infections
Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
The objective of this study is to monitor Health Outcomes of Interest (HOI) in participants with human immunodeficiency virus-1 (HIV-1) infection following treatment with Raltegravir.
- Trial name
- NCT01078246
- Volunteers
- 7,124 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV, Combination Therapy
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
The purpose of this study is to determine whether HIV-1-infected patients, who are virologically suppressed on a regimen of 2 nucleoside reverse transcriptase inhibitors plus any third agent but are experiencing safety and/or…
- Trial name
- SPARTAN (NCT01332227)
- Testing
- Atazanavir, Ritonavir (heat-stable), Raltegravir
- Where
- 38 sites in United States, France and 5 more
- Volunteers
- 132 people
- Sponsor
- Bristol-Myers Squibb
HIV
A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
Open label, two year study of the clinical efficacy of the combination of FTC, Tenofovir, and Nevirapine. Sixty HIV infected patients without previous exposure to antiretroviral therapy will be enrolled.
- Trial name
- NCT00344461
- Testing
- Nevirapine, FTC, and Tenofovir
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Maryland, Baltimore
HIV-1 Infection
A Study of the Safety and Antiretroviral Activity of 3BNC117
This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of…
- Trial name
- NCT02588586
- Testing
- 3BNC117, Antiretroviral Treatment Interruption
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Rockefeller University
Human Immunodeficiency Virus (HIV)
Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
This research is being done to learn how seminal fluid affects the lining of the colon, and whether this might make it easier for HIV to get into the body and cause infection.
- Trial name
- NCT01053741
- Testing
- Radiolabeled autologous seminal fluid, Radiolabeled Normosol-R
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Kaposi's Sarcoma, HIV Infections
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
This study will examine the safety and effectiveness of the experimental drug bevacizumab for treating both non-acquired immune deficiency syndrome (AIDS) and AIDS-associated Kaposi's sarcoma (KS).
- Conditions
- Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
- Trial name
- NCT00055237
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of…
- Trial name
- SONNET (NCT01199731)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
- Where
- 41 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare